01—Abstract
Summary
Summary of the 8-K filed February 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company (LLY) announced on February 7, 2024, its successful issuance of $6.45 billiona in aggregate principal amount of senior notes through an underwriting agreement with several major financial institutions.
This offering comprised five tranches of notes with varying maturities ranging from 2027 to 2064 and coupon rates from 4.500% to 5.100%. The net proceeds from this significant debt issuance, totaling approximately $6.45 billionb after deducting underwriting discounts, are expected to bolster Lilly's financial flexibility. This substantial capital raise indicates Lilly's strategic approach to financing its operations, research and development, and potential future growth initiatives.
The diverse maturity profile of the notes allows for a structured approach to debt management. Investors should note that the company retains the option to redeem these notes under specific conditions, and the principal amount may become immediately due and payable in the event of a default, as outlined in the indenture agreement.
02—Key points
Key Highlights
- Eli Lilly raised approximately $6.45 billion in net proceeds from the issuance of senior notes.
- The offering included five series of notes with aggregate principal amounts totaling $6.45 billion.
- Note maturities range from 2027 to 2064, with coupon rates between 4.500% and 5.100%.
- The issuance was facilitated through an underwriting agreement with a syndicate of prominent investment banks.
- The offering was registered under a Form S-3 registration statement, indicating prior SEC review.
- The company has the option to redeem the notes, in whole or in part, under specified terms.
- An Event of Default could lead to the acceleration of principal repayment for the notes.
03—Questions
Frequently Asked Questions
What is the primary purpose of this debt issuance for Eli Lilly?
The filing does not explicitly state the use of proceeds for this debt issuance. However, such significant capital raises are typically used to fund ongoing operations, invest in research and development, support potential acquisitions, or manage existing debt obligations. Investors can infer that this strengthens Lilly's financial position to pursue its strategic objectives.
What are the interest rates and maturity dates of the new notes?
The notes issued have the following terms: 4.500% Notes due 2027, 4.500% Notes due 2029, 4.700% Notes due 2034, 5.000% Notes due 2054, and 5.100% Notes due 2064.
How much money did Eli Lilly raise in total from this offering?
Eli Lilly raised approximately $6.45 billion in net proceeds after deducting underwriting discounts and before estimated offering expenses.
What is the significance of the Form S-3 registration statement mentioned?
A Form S-3 registration statement allows well-known seasoned issuers like Eli Lilly to register securities offerings efficiently. It indicates that the company has met certain SEC reporting requirements and provides a framework for future, similar offerings.
04—Continue